Everest Kanto Cylinder Ltd Q2 FY26 Earnings Analysis

- India Business Growth: Expected 10% - 15% growth in sales/revenue for the coming quarters and FY26 (Page 6). - Margin Expectations: Sustainable margins around 13% - 14% in India, with efforts to achieve higher but conservative guidance maintained (Page 6 and 8). - US Business: Strong order book (~USD 70 million) and expected to continue delivering good margins and growth, with a planned product pipeline for 1.5-2 years (Page 4). - Egypt and Mundra Facilities: Capacity additions of 120,000 cylinders (Egypt) and 200,000 cylinders (Mundra) with commercial production starting within FY26; significant revenue impact expected from FY27 onwards (Page 4 and 7). - Order Book: India maintains an order book around Rs. 60 crore consistently (Page 7). - Overall, healthy demand visibility and capacity expansions position the company well for the next phase of growth (Page 3).

- India business growth expected at 10%-15% annually going forward. - India business sustainable margins targeted conservatively at 13%-14%, despite recent sharp rise to 17%. - US business expected to sustain good margins based on management discussions. - UAE business expected to remain moderate with ongoing challenges. - Capacity expansions in Mundra (India) and Egypt to come onstream during current fiscal, with significant impact visible from FY27 onwards. - New sectors like biogas and semiconductors seen as growth opportunities with potential for future expansion. - Overall, with healthy demand visibility, capacity additions, and expanding applications, company well-positioned for next phase of growth and value creation. - CAPEX largely funded internally with some borrowing at ~9% interest rate, maintaining near net debt-free status.

- Current CAPEX includes: - Egypt plant: Rs. 120 crore (around Rs. 70 crore spent so far) - India (Mundra) plant: Rs. 125 crore (around Rs. 90 crore spent so far) - Capacity additions: - Egypt: 120,000 units - Mundra, India: 200,000 units - Egypt plant expected to start trial production in Oct-Nov 2025, with commercial production likely within 2-3 months after; major impact visible from FY27. - Mundra plant expected to be ready by last quarter of FY26, with commercial production starting before year-end. - CAPEX funded through internal accruals and borrowings; company aims to remain net debt free. - Strategic focus remains on cylinder business with ongoing product development; exploring applications in CNG, hydrogen, biogas, and semiconductors. - No current plans to move beyond the cylinder product line, but company investing in new tech and product roadmap within core business.

- The company is undertaking CAPEX funded through a mix of internal accruals and borrowings. - They expect to continue being net debt free despite some borrowings for CAPEX. - Current gross debt stands at Rs. 140 crores consolidated. - The borrowings include term loans with an interest rate around 9%. - No explicit mention of raising funds through equity in the transcript. - The management emphasizes a conservative approach to margins and financial management but did not indicate plans for equity fundraising. - Overall, future fundraising appears focused on debt (term loans) to support CAPEX, with no current plans stated for equity issuance.

- The current order book in India business is around Rs. 60 crore, and the company continuously receives and executes orders to maintain this level. - For the US business, the order book stands at approximately USD 70 million, with products planned for 1.5 to 2 years ahead. - The US market order book is dynamic, with continuous execution and incoming new orders. - The company expects steady growth in India business, projecting 10% to 15% growth supported by the current order book. - No specific order book details for UAE or Egypt were provided, but Egypt's plant commissioning is anticipated in the near term, potentially impacting orders in FY27.